What is new with Trump pharma in September 2026 is a rapid expansion of the administration's drug-pricing strategy: on August 31, 2026 the White House announced most-favored-nation (MFN) pricing deals with nine more drugmakers, bringing the total to 26 manufacturers. MFN means a pledge that Medicaid will pay the lowest price a drug fetches in other wealthy countries.
Alongside the deals, a 100% tariff on patented drugs is now phasing in, the TrumpRx cash-pay site keeps adding brands, and a Supreme Court ruling has reshaped which tariff powers are legally sound. For a reader tracking policy accountability, the headline and the fine print point in different directions. The government describes broad coverage and billions in new investment; independent analysts and court records show the benefits are narrower and legally contested than the announcements suggest.
Table of Contents
- What the August 31 deals actually cover
- Will this lower what you pay at the pharmacy?
- TrumpRx and its pricing gap
- The 100% tariff and how the deals dodge it
- The court record you should watch
- Frequently Asked Questions
What the August 31 deals actually cover
The nine new companies are Alcon, Astellas, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva, and UCB. According to Pharmacy Times' summary of the White House fact sheet, each pledged that medicaid will pay the lowest price the drug carries among comparable wealthy nations. The administration says the nine deals push the total to 26 manufacturers, covering roughly 89% of the branded U.S. drug market, as Axios reported on August 31.
That "89%" figure describes market share of branded drugs, not the share of what any individual patient pays. In exchange, the companies committed at least $19.6 billion in near-term U.S. manufacturing investment and received a three-year suspension of pharmaceutical tariffs for aligning with MFN pricing, per the White House fact sheet. The tariff relief is a direct incentive, not a side effect.
Will this lower what you pay at the pharmacy?
For most insured Americans, probably not directly. Analysts told STAT News on September 2 that the deals center on Medicaid and cash-pay channels, not the commercial insurance that covers most working-age people. That distinction matters.
If you get drugs through an employer plan or a Marketplace policy, your out-of-pocket cost is set by your plan's formulary and copay tiers, which these agreements do not touch. The clearest potential winners are Medicaid programs and people who pay cash without insurance. Even there, the price you see depends on the specific drug and channel, so treat any single "lowest price" claim as something to check against your own prescription.
TrumpRx and its pricing gap
trumpRx.gov is the federal direct-to-consumer, cash-pay platform launched in February 2026. It keeps growing: TechTarget reports that AbbVie, adding Humira, and Genentech joined as the tenth and eleventh large participants.
But the "most-favored-nation" branding does not always hold for cash buyers. A New York Times analysis, summarized by Wikipedia, found TrumpRx prices are often not lower than other wealthy countries' prices, and in some cases roughly double them. If you are considering TrumpRx, compare before you buy:.
📨 Get Free Accountability Coverage Alerts
Free · No spam · Unsubscribe anytime
- Check the TrumpRx price against your insurance copay for the same drug.
- Compare it with a pharmacy discount-card price.
- For a maintenance drug, price a 90-day supply, not just a single fill.
The 100% tariff and how the deals dodge it
A separate lever is trade policy. Trump's April 2, 2026 Section 232 proclamation imposes a 100% tariff on patented pharmaceuticals and their active ingredients, according to law firm Crowell & Moring. It took effect July 31, 2026 for large firms and September 29, 2026 for others, with generics, biosimilars, and orphan drugs exempt. The tariff is the stick behind the MFN carrot.
As Al Jazeera reported, firms with a signed MFN deal and active U.S. facility construction pay 0%; those building without a pricing deal pay 20%, rising to 100% after four years. That structure explains the rush to sign. A deal is not only a pricing pledge; it is the difference between a zero tariff and one that could double an import's cost.
The court record you should watch
The legal ground is not settled. On February 20, 2026, the Supreme Court held that the International Emergency Economic Powers Act (IEEPA) does not authorize presidential tariffs, invalidating an earlier tariff basis, according to JD Supra. The pharmaceutical tariffs rest on separate authority — Section 232, a national-security trade statute — so that ruling does not strike them down.
But refund and challenge proceedings are ongoing at the U.S. Court of International Trade, meaning the tariff rates driving these deals could still shift. For accountability purposes, the takeaway is concrete: the coverage figures and investment totals come from the administration's own fact sheets, the skepticism comes from independent analysts, and the enforcement mechanism sits in front of a court that has already rejected one tariff theory this year.
Frequently Asked Questions
How many drugmakers now have MFN deals?
Twenty-six manufacturers, after the nine announced August 31, 2026, covering about 89% of the branded U.S. drug market by the administration's count.
Are generic drugs affected by the 100% tariff?
No. Generics, biosimilars, and orphan drugs are exempt; the tariff targets patented drugs and their active ingredients.
Does TrumpRx guarantee the lowest global price?
No. A New York Times analysis found its cash prices are often not lower than other wealthy nations', and sometimes roughly double.
You Might Also Like
- What Is New With Trump Science in August 2026? Latest court filings and agency records and Key Takeaways
- What Is New With Trump Medicare in August 2026? Latest court filings and agency records and Key Takeaways
- What Is New With Trump Lobbying in August 2026? Latest court filings and agency records and Key Takeaways